The economic impact of blue-light filtering intraocular lenses on age-related macular degeneration associated with cataract surgery: a third-party payer's perspective

References

• Wang JJ, Klein R, Smith W, et al. Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: Pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology 2003;110:1960–7
   PubMed Web of Science ®Google Scholar
• Nilsson SE. Are there advantages in implanting a yellow IOL to reduce the risk of AMD? Acta Ophthalmol Scand 2004;82:123–5
   PubMedGoogle Scholar
• Sliney DE and Wolbarsht M. Safety with Lasers and Other Optical Sources: A Comprehensive Handbook, 4th edn. New York and London: Plenum Press, 1985
   Google Scholar
• Nilsson SE, Textorius O, Andersson B, et al. Does a blue-light absorbing intraocular material protect the neuro-retina and pigment epithelium better than currently used materials? Laser Light Ophthalmol 1990;3:1–10
   Google Scholar
• Sparrow JR, Miller AS, Zhou J. Blue light-absorbing intraocular lens and retinal pigment epithelium protection in vitro. J Cataract Refract Surg 2004;30:873–8
   Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET, Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–16
   PubMed Web of Science ®Google Scholar
• TAP Investigators. Photodynamic therapy of subfoveal choiroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of two randomized controlled trials – TAP Report #2. Arch Ophthalmol 2001;119:198–207
   PubMed Web of Science ®Google Scholar
• Shah VA, Gupta SK, Shah KV, et al. TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD. Ophthalmic Epidemiol 2004;11:43–51
   PubMed Web of Science ®Google Scholar
• Garattini L, Castelnuovo E, Lanzetta P, et al. Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments. A multicenter, prospective 1-year study. Eur J Health Econ 2004;5: 22–7
   Google Scholar
• A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C, and E, and beta carotene for age-related cataract and vision loss: AREDS Report No. 9. Arch Ophthalmol 2001;119: 1439–52
   Google Scholar
• Alcon Labs [online]. Available from http://www.alconlabscom/us/eo/products [Last accessed 31 Aug 2005]
   Google Scholar
• Department of Health and Human Services: Office of the Inspector General. Medicare payments to ambulatory surgical centers for intraocular lenses. February 2004 OEI-06–02–00710
   Google Scholar
• Desai P, Minassian DC, Reidy A. National cataract surgery survey 1997–8: a report of the results of the clinical outcomes. Br J Ophthalmol 1999;83: 1336–40
   Google Scholar
• The Academy of Managed Care Pharmacy Formulary Submissions: Health system guidelines for manufacturers. Version 2.1 – April 2005 [online]. Available from http://www.amcp.org [Last accessed 23 May 2006]
   Google Scholar
• Klein R, Klein BE, Jensen SC, et al. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmol 1997;104:7–21
   PubMed Web of Science ®Google Scholar
• Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991;109:1242–57
   Google Scholar
• Rechtman E, Ciulla TA, Criswell MH, et al. An update on photodynamic therapy in age-related macular degeneration. Expert Opin Pharmacother 2002;3:931–8
   PubMedGoogle Scholar
• Gordis L. Epidemiology. In: More on Risk: Estimating the Potential for Prevention. Philadelphia, Pennsylvania: W. B. Saunders Company, Chapter 11, pp.155–62, 19??
   Google Scholar
• Current Procedural Terminology 2003, 4th edn – revised. Chicago, IL: American Medical Association, 2003
   Google Scholar
• Das T, Sharma S. Current management strategies of acute postoperative endophthalmitis. Semin Ophthalmol 2003;18:109–15
   PubMedGoogle Scholar
• Vigamox package insert. Alcon Laboratories. [online]. Available from http://www.alconlabs.com/us/eo/products/pharma/Vigamox_main.jhtml [Last accessed 23 May 2006]
   Google Scholar
• Redbook. Pharmacy’s Fundamental Reference, 2004 (Ed. Montvale, NJ). Medical Economics, Thompson Healthcare, 2004
   Google Scholar
• Available from http://www.drugstore.com [Last accessed 23 Oct 2005]
   Google Scholar
• National Fee Analyzer. Charge Data for Evaluating Fees Nationwide, 2004 edn. Salt Lake City, UT: Ingenix St. Anthony Publishing/Medicode, 2004
   Google Scholar
• Comer GM, Ciulla TA, Griswell MH, et al. Current and future treatment options for non-exudative and exudative age-related macular degeneration. Drugs Aging 2004;21:967–92
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Stein JD, et al. Age-related macular degeneration: Economic burden and value-based medicine analysis. Can J Ophthalmol 2005;40:277–87
   PubMed Web of Science ®Google Scholar
• Braunstein RE, Sparrow JR. A blue-blocking intraocular lens should be used in cataract surgery. Arch Ophthalmol 2005;123:547–9
   PubMed Web of Science ®Google Scholar